Aarkstore - Frontier Pharma: Alzheimers Disease - Identifying and Commercializing First-in-Class Innovation

1
Aarkstore - Frontier Pharma Alzheimers Disease -
Identifying and Commercializing First-in-Class
Innovation
Pharmaceuticals Healthcare  Market Research
Reports
2
Summary

• Large and Innovative Pipeline The active
  Alzheimers Disease (AD) pipeline is populated
  with 583 products, with a highly diverse range of
  molecular targets. GBI Research analysis revealed
  a high degree of innovation in this indication,
  with 46 of the pipeline being first-in-class
  products, acting on over 40 first-in-class
  molecular targets. In addition, the pipeline is
  characterized by the strong presence of therapies
  that target multiple components implicated in the
  amyloid cascade, several molecular targets of
  which are known to trigger familial AD. Given
  that the currently approved therapies for AD are
  limited to acetylcholinesterase inhibitors and
  glutamate receptor antagonists, the pipeline
  offers a broad range of treatment options that
  may possess disease-modifying properties.
  However, evaluation of the Preclinical and
  clinical evidence for their therapeutic potential
  reveals that the novelty of the molecular target
  is not sufficient to effectively reduce the rate
  of AD progression in human patients.

3
Scope

• The report covers and includes - - A brief
  introduction to AD, including symptoms,
  pathophysiology, and overview of pharmacotherapy
  and treatment algorithms- The changing molecular
  target landscape between market and pipeline and
  particular focal points of innovation in the
  pipeline- A comprehensive review of the pipeline
  for first-in-class therapies, analyzed on the
  basis of stage of development, molecule type and
  molecular target- Identification and assessment
  of first-in-class molecular targets with a
  particular focus on early-stage programs for
  which clinical utility has yet to be evaluated,
  as well as literature reviews of novel molecular
  targets- Assessment of the licensing and
  co-development deal landscape for AD therapies
  and benchmarking of deals involving
  first-in-class versus non-first-in-class-products
  

4
Reasons to buy

• The report will assist business development
  and enable marketing executives to strategize
  their product launches, by allowing them to - -
  Understand the focal shifts in molecular targets
  in the AD pipeline- Understand the distribution
  of pipeline programs by phase of development,
  molecule type and molecular target- Access a
  scientific and clinical analysis of
  first-in-class developmental programs for AD,
  benchmarked against non-first-in-class targets-
  Access a list of the first-in-class therapies
  potentially open to deal-making opportunities

5
Table of Content

• 1.1 List of Tables 31.2 List of Figures
  32 Executive Summary 43 The Case for Innovation
  64 Clinical and Commercial Landscape 115
  Assessment of Product Pipeline Innovation 216
  Signaling Network, Genetics and Innovation
  Alignment 357 First-in-Class Target Evaluation
  398 Deals and Strategic Consolidations 759
  First-In-Class Molecules not Involved in
  Licensing or Co-development Deals 8610 Appendix
  89

6
List of Tables

• Table 1 Mini-Mental State Exam, 2005 15Table 2
  Alzheimers Disease Assessment Scale, Cognitive
  Subscale, 1984 16

7
List Of Figures

• Figure 1 Innovation Trends in Product Approvals,
  19872012 6Figure 2 Sales Performance of
  First-in-Class and Non-First-in-Class Product
  post Marketing Approval, 20062013 8Figure 3
  Sales Performance of Central Nervous System
  First-in-Class and Non-First-in-Class Products
  post Marketing Approval, 20062013 8Figure 4
  Alzheimers Disease, Global, Developmental
  Pipeline 22Figure 5 Alzheimers Disease,
  Global, Established and First-in-Class Pipeline
  25Figure 6 Alzheimers Disease, Global,
  Established Developmental Pipeline Part 1, 2014
  27Figure 7 Alzheimers Disease, Global,
  Established Developmental Pipeline Part 2, 2014
  28Figure 8 Alzheimers Disease, Global,
  Established Developmental Pipeline Part 3, 2014
  29Figure 9 Alzheimers Disease, Global,
  Established Developmental Pipeline Part 4, 2014
  30Figure 10 Alzheimers Disease, Global,
  First-in-Class Developmental Pipeline Part 1,
  2014 32

Browse full report Or Sample Request
_at_ http//www.aarkstore.com/pharmaceuticals-healthc
are/105777/frontier-pharma-alzheimers-disease-iden
tifying-and-commercializing-first-in-class-innovat
ion
8
Related Reports

• 2015 Global Infectious Disease Molecular
  Diagnostics Market Country Forecasts, Supplier
  Shares, Emerging Technologies, Competitive
  Landscape
• 2015 European Infectious Disease Molecular
  Diagnostics Market Country Forecasts, Supplier
  Shares, Emerging Technologies, Competitive
  Landscape
• 2015 France Infectious Disease Molecular
  Diagnostics Market Country Forecasts, Supplier
  Shares, Emerging Technologies, Competitive
  Landscape
• 2015 Germany Infectious Disease Molecular
  Diagnostics Market Country Forecasts, Supplier
  Shares, Emerging Technologies, Competitive
  Landscape
• Global Healthcare IT Integration Market 2015-2019
• Dialysis Catheters Market in the US 2015-2019
• Global Immunodiagnostics Market 2015-2019
• Pharmaceuticals Healthcare Market Research
  Reports

9
Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
10
Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953